Prostate cancer survivors during the era 2005-2013, as you'll see from our tag cloud (sidebar), were bombarded by Dendreon's controversial campaign to speed FDA approval of its immunotherapy vaccine Provenge. Since then, Provenge hype has calmed down, while the push for Abiraterone acetate (Zytiga) has heated up.
Abiraterone (generic name) aka Zytiga (brand name) is a high-powered castration drug FDA approved for use with 10-mg prednisone as a treatment for men with metastatic CRPC. Compared to Provenge, which costs around $90,000 for a course of treatment, Zyiga costs about $5,000 a month with expected follow-up doses for around eight months.
Janssen, Zytiga's manufacturer, is pushing to extend the drug for men with high-risk nonmetastatic (M0) castration-resistant prostate cancer (CRPC). According to a study by Dr. David Crawford and colleagues,, abiraterone (Xytiga) "significantly lowered PSA levels with a consistent toxicity profile in men with high-risk nonmetastatic (M0) castration-resistant prostate cancer (CRPC)."
...continue reading Zytiga Lowers PSA in men with high-risk prostate cancer, at a cost in side-effects